Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Want to see CH:SANN full AI Analyst Report?
SANN Stock Chart & Stats
CHF17.62
-CHF0.14(-0.88%)
At close: 4:00 PM EST
CHF17.62
-CHF0.14(-0.88%)
Day’s Range― - ―
52-Week RangeCHF9.38 - CHF18.36
Previous CloseN/A
Volume24.19K
Average Volume (3M)55.85K
Market Cap
CHF240.51M
Enterprise ValueCHF318.99M
Total Cash (Recent Filing)CHF18.40M
Total Debt (Recent Filing)CHF76.30M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Apr 28, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,845,271
10 Day Avg. Volume57,231
30 Day Avg. Volume55,851
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.68
Price to Sales (P/S)4.02
P/FCF Ratio-4.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF30.00Price Target Upside70.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.13
Revenue Forecast (FY)CHF112.45M
Bulls Say, Bears Say
Bulls Say
Licensing Partnership And Regional ExpansionAnalyst observes that licensing the program to an experienced regional partner transfers development, manufacturing, and commercialization responsibilities, reducing operational risk and improving prospects for market entry in Japan and nearby Asia‑Pacific markets.
Orphan Exclusivity And Local Commercial ProtectionAnalyst highlights that long orphan drug exclusivity combined with exclusive distribution rights in Switzerland secures local commercial protection and limits near‑term competition in that market.
Regulatory ApprovalAnalyst notes that Swissmedic approval based on a pivotal clinical trial strengthens the drug's registration credentials for European markets and may support smoother regulatory assessments in additional jurisdictions.
Bears Say
Reimbursement Uncertainty In SpainAnalyst warns that final reimbursement conditions determined by the Directorate‑General of Pharmacy create uncertainty about exact market access terms, which could affect pricing, coverage, and uptake in Spain.
Santhera Pharmaceuticals Holding News
SANN FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was CHF9.38 and its highest was CHF18.36 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is CHF240.51M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Apr 28, 2026 which is today.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Currently, no data Available
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate is -0.45.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 14,845,271 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in CH:SANN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
SANN Company Deck
SANN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summariesSANN Stock 12 Month Forecast
Average Price Target
CHF30.00
▲(70.26% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---